Nutzen-Risiko-Bewertung neuer Wirkstoffe als Grundlage für Priorisierungsentscheidungen in der Hämatologie/Onkologie: Methodische Herausforderungen und Lösungsansätze
Creator
Ludwig, Wolf-Dieter
Schildmann, Jan
Bibliographic Citation
Onkologie 2011; 34 Suppl 1: 6-10
Abstract
Innovations in the drug treatment of cancer patients pose several medical and ethical challenges. The increasing incidence and prevalence of cancer, in combination with the availability of new and usually highly expensive anticancer drugs, are associated with a significant increase in the general costs for the treatment of cancer patients. Therefore, the development of scientific strategies for judgments on benefits is indispensable. In this paper, the authors analyze the benefit assessment and the benefit-risk assessment as a foundation for decisions on prioritization in hematology and oncology. In a first step, regulatory aspects and shortcomings regarding the design of clinical trials in oncology before and after approval of anticancer drugs are identified as factors that contribute to difficulties in establishing the effectiveness of new drugs entering the health care market. The authors will conclude with suggestions for the improvement of benefit-risk analyses and the generation of scientific data necessary for such analyses.
Permanent Link
Full Text from Publisherhttp://hdl.handle.net/10822/1019657
Date
2011Collections
Metadata
Show full item recordRelated items
Showing items related by title, author, creator and subject.
-
The Financing of Drug Trials by Pharmaceutical Companies and Its Consequences: Part 2: A Qualitative, Systematic Review of the Literature on Possible Influences on Authorship, Access to Trial Data, and Trial Registration and Publication
Schott, Gisela; Pachl, Henry; Limbach, Ulrich; Gundert-Remy, Ursula; Lieb, Klaus; Ludwig, Wolf-Dieter (2010-04)In recent years, a number of studies have shown that clinical drug trials financed by pharmaceutical companies yield favorable results for company products more often than independent trials do. Moreover, pharmaceutical ...